Contineum Therapeutics Inc. Class A (CTNM)
NASDAQ: CTNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $340.83M
- EPS (TTM)
- -$1.77
- Dividend yield
- None
- 52-week range
- 6.73 – 17.79
- Day range
- 8.50 – 9.09
- Volume / Avg
- 369.21K / 776.03K
- Beta
- —
- Shares outstanding
- 35.35M
52-week range
CTNM stock today
On Nov 20, CTNM ended the session at $8.68, shedding $0.36 (3.98%), versus the S&P 500's 3.70% decline. Trading was light, with 369.21K shares changing hands, about 48% of the average daily volume. At this level, CTNM sits near the bottom of its 52-week range of $6.73 to $17.79: 51.2% below the high, set on Sep 3, 2026 and 29.1% above the low.
CTNM is down 24.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.7%. Contineum Therapeutics has posted a net loss over the last twelve months (EPS of -$1.77), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Contineum Therapeutics
Company profileContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Carmine N. Stengone MBA, MS
- Headquarters
- San Diego, CA
- Employees
- 51
- IPO year
- 2024
- Website
- contineum-tx.com
Financial highlights
Full financialsContineum Therapeutics reported a net loss of $60.0 million, compared with a loss of $42.3 million a year earlier. Diluted earnings per share came in at -$2.17.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | $0 | $50.00M |
| Growth | — | -100.00% | — |
| Net income | $-59.98M | $-42.26M | $22.72M |
| EPS (diluted) | $-2.17 | $-2.18 | $0.08 |
Analyst forecast
ForecastConsensus (8 analysts)
buy
Avg. price target
$21.43+146.89%
- Strong buy 1
- Buy 5
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.49 vs $-0.45
- Surprise
- -8.89%
CTNM news
All CTNM newsContineum Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MPLTMapLight Therapeutics Inc. | 5.94 | -7.48% | $330.12M | vs CTNM |
| INOInovio Pharmaceuticals Inc. | 1.76 | +2.92% | $329.66M | vs CTNM |
| LRMRLarimar Therapeutics Inc. | 3.14 | -2.48% | $328.55M | vs CTNM |
| PEPGPepGen Inc. | 3.78 | -3.82% | $356.31M | vs CTNM |
| ASPEAspen Neuroscience Inc. | 12.42 | +0.24% | $361.16M | vs CTNM |
| AVIRAtea Pharmaceuticals Inc. | 3.96 | +0.76% | $318.00M | vs CTNM |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs CTNM |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs CTNM |
Indexes, lists and sector
Contineum Therapeutics stock FAQ
What is Contineum Therapeutics's stock price today?
CTNM last traded at $8.68 as of Nov 20, 4:00 PM EST, down 3.98% on the day. Prices are delayed at least 15 minutes.
Who is Contineum Therapeutics's CEO?
Mr. Carmine N. Stengone MBA, MS is the chief executive officer of Contineum Therapeutics Inc. Class A, which has about 51 employees.
What is the CTNM 52-week high?
The 52-week high for CTNM is $17.79 and the 52-week low is $6.73. The stock is currently 51.2% below its high.